Recursion raises $200 M in follow‑on offering and receives $10 M Sanofi milestone

Recursion Pharmaceuticals announced a $200 million common‑stock offering that lifts its cash balance to $561 million and extends its cash runway to 2029. On the same day Sanofi exercised an option on the first development candidate from their collaboration, triggering a $10 million milestone payment and bringing total payments from Sanofi to $144 million. The optioned oral small‑molecule candidate is slated to start Phase 1 trials in 2027, and Recursion remains eligible for more than $300 million in additional milestones and royalties.

The financing gives Recursion enough cash to fund operations through 2029, reducing short‑term funding risk (the company says). The $10 million milestone will be recognized as revenue in Q3 2026, adding immediate earnings and further aligning the partnership with Sanofi.

  • 1Recursion raised $200 million via an underwritten common‑stock offering.
  • 2The offering increased cash on hand to $561 million and extends the cash runway into 2029.
  • 3Sanofi optioned the first development candidate, triggering a US$10 million milestone payment.
  • 4The milestone brings total upfront and milestone payments received from Sanofi to $144 million.
  • 5Recursion may earn more than $300 million in additional milestones and royalties if the candidate succeeds.
  • 6The optioned oral small‑molecule candidate is expected to enter Phase 1 clinical trials in 2027.

Sources